Biosimilars

A biologic drug that closely resembles another biologic drug (called a reference drug) has been approved by the U.S. Food and Drug Administration (FDA). Biosimilars and reference drugs are made from living organisms, but they can be made in different ways and froms lightly different substances. To qualify as a biosimilar, a biologic drug must demonstrate that it is safe, works well, and functions like its reference drug.The drug should also be administered in the same manner, in the same dose and condition as the reference drug. A biosimilar drug must be approved by the FDA and may cost less than a reference drug.



 


    Related Conference of Biosimilars

    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 14-15, 2026

    6th International Conference on Pharmaceutical Chemistry

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    December 14-15, 2026

    5th Global Summit on Pharmaceutical Research

    Paris, France
    January 26-27, 2027

    22nd Annual Meet on Pharmaceutical Sciences

    Paris, France
    April 27-28, 2027

    10th European Biopharma Congress

    Paris, France

    Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in